Whirlpool’s (NYSE: WHR) stock downtrend may not be over; however, the technical, fundamental, and market forces are aligning, suggesting downside is severely limited and the upside potential is robust.
The chart, whether it be daily, monthly, or weekly price action, reflects a market that i.... |
Good MorningU.S. markets remain buoyant with the Dow briefly topping 48,000 and both the NASDAQ and S&P 500 hitting all-time highs at points this year. The Magnificent Seven continue to exert outsized influence—an equal-weight ETF tied to them is up nearly 20% YTD—and tech names stayed in focus with NVIDIA among the most active stocks.
The energy sector took the lead early on, with an early winter and high LNG demand driving natural gas prices up, which in turn boosted interest in related ETFs and stocks. Three major energy companies raised their dividends, highlighting cash returns to investors. ExxonMobil extended its streak with another increase, keeping its long-running payout intact and maintaining a roughly 3.5% yield.
Still, signs of strain in the broader economy are emerging: past-due utility balances rose by about 9.7% year over year, a warning sign for household finances. Healthcare saw pricing moves as Novo Nordisk cut Wegovy list prices, but affordability concerns remain for the uninsured. Corporate buybacks also grabbed attention as Trade Desk, Thermo Fisher, and Tapestry used repurchases to signal confidence. Featured: Elon Musk's Next Big AI Project Could Open This Month (Ad) 
| Consumer Discretionary | |
Whirlpool’s (NYSE: WHR) stock downtrend may not be over; however, the technical, fundamental, and market forces are aligning, suggesting downside is severely limited and the upside potential is robust.
The chart, whether it be daily, monthly, or weekly price action, reflects a market that i... Read the Full Story |
| From Our Partners | | Jeff Brown, founder and CEO of Brownstone Research, says he has uncovered what he calls one of the biggest discoveries of his career tied to the ongoing AI boom.
Brown is pointing to a key date, October 20, and is highlighting five AI-related opportunities outside the traditional stock market that most investors have never heard of. | | Click here to see the full research before October 20 |
| Communication Services | |
The tech sell-off that began in late October continued through the first half of November. While the selling was initially isolated to a handful of the Magnificent Seven stocks and others leveraged to AI—including Palantir Technologies (NASDAQ: PLTR), shares of which are down nearly 13% sinc... Read the Full Story |
| Technology | |
Shares of quantum computing firm D-Wave Quantum Inc. (NYSE: QBTS) seem to be cooling, despite a third-quarter earnings report that was notably strong on multiple fronts. The stock has plunged by more than 38% in the last month, essentially reversing all gains achieved since mid-September 2025. T... Read the Full Story |
| From Our Partners | | Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals.
In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then. | | Watch the Cybercab footage and judge Elon Musk's technology yourself |
| Communication Services | |
Warren Buffett's Berkshire Hathaway (NYSE: BRK.B) just released its much-anticipated Q3 13F filing, revealing what portfolio moves the Oracle of Omaha’s investment firm made during the quarter.
Notably, Buffett is set to retire at the end of 2025 and is leaving Berkshire with a record amo... Read the Full Story |
| Energy | |
Three energy behemoths are lifting their dividends—a Dividend Aristocrat, a huge nuclear name, and one of the world’s largest oil exploration and production companies. For income-focused investors, these moves offer compelling entry points across oil and nuclear energy, whether you're ... Read the Full Story |
| From Our Partners | | Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history.
The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google.
Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight. | | Click here to see the full details on Musk's next big move |
| Healthcare | |
The Magnificent Seven—the tech-focused firms among the largest and most influential companies in the world—absolutely dominate the broader market, accounting for a full one-third of the S&P 500. The Roundhill Magnificent Seven ETF (BATS: MAGS) provides equal-weight exposure to thes... Read the Full Story |
| Consumer Staples | |
Insider buying at the WD-40 Company (NASDAQ: WDFC) signals value, as the stock trades near its long-term lows and at the low end of its historical price-to-earnings (P/E) range. While its 32x current-year earnings is a premium price, it reflects a solid outlook for steady top-line growth, margin i... Read the Full Story |
| Finance | |
Small-cap stocks, loosely defined as companies with market capitalizations up to just a few billion dollars, occupy a unique and often underappreciated corner of the market. They don’t always command headlines, and many come with higher volatility than their large-cap counterparts. Some smal... Read the Full Story |
| Markets | |
Winter is coming, and this became apparent last week as brisk temperatures descended on many northern states as the calendar flipped to November. The first blast of arctic air usually gets Americans thinking about holidays and family gatherings, but surging energy prices are also top of mind, and ... Read the Full Story |
| Technology | |
As 2025 draws to a close, the AI boom remains the market’s defining theme.
Yet, beneath the surface of trillion-dollar chipmakers and software giants, a different kind of AI story has been unfolding.
Appian Corporation (NASDAQ: APPN), long recognized for its process automation software,... Read the Full Story |
| Tuesday's Early Bird Stock Of The Day Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. | Should I Buy Boston Scientific Stock? BSX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Boston Scientific was last updated on Monday, October 12, 2026 at 7:16 PM.
Boston Scientific Bull Case -
Boston Scientific Co. is currently trading at $43.78, which is near its 52-week low of $41.38, offering a potential entry point for value-oriented investors. The stock has a price-to-earnings ratio of 17.73, which is relatively low for a medical technology company, suggesting that the market may be undervaluing the company's future earnings potential compared to its historical performance.
-
The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.86, which beat the consensus estimate of $0.83. Revenue also exceeded expectations at $5.44 billion, up 7.5% year-over-year, indicating robust demand for its medical devices and effective execution of its business strategy.
-
Boston Scientific Co. has a low beta of 0.58, meaning its stock price tends to be less volatile than the overall market. This characteristic can make it a suitable investment for risk-averse investors or those looking to stabilize their portfolio during periods of market uncertainty.
-
The company has a strong balance sheet with a current ratio of 1.24 and a debt-to-equity ratio of 0.43, indicating good liquidity and manageable leverage. This financial health provides a buffer against economic downturns and supports the company's ability to invest in research and development.
-
Boston Scientific Co. is a leader in the medical technology sector, offering a diverse portfolio of devices for cardiovascular care, endoscopy, urology, and neuromodulation. This diversification reduces reliance on any single product line and positions the company to benefit from growing demand for minimally invasive procedures.
Boston Scientific Bear Case -
The stock has experienced a significant decline, reaching a 52-week low of $41.38, which is a substantial drop from its 52-week high of $105.65. This downward trend may indicate underlying issues with the company's business model or market conditions that could continue to pressure the stock price.
-
Analysts have recently lowered their price targets for Boston Scientific Co., with Leerink Partners cutting its target from $60.00 to $55.00 and Wells Fargo lowering its target from $50.00 to $48.00. These reductions suggest that analysts are becoming more cautious about the company's future growth prospects.
-
The company's guidance for the current fiscal year is below the consensus estimate, with Boston Scientific Co. projecting earnings per share of $3.280 to $3.320, while analysts expect $3.360. This gap may indicate that the company is facing challenges in meeting market expectations, which could lead to further stock price declines.
-
Boston Scientific Co. is facing legal challenges, including a patent infringement lawsuit against Johnson & Johnson over a heart procedure tool. Such litigation can be costly and distracting for management, potentially impacting the company's operational focus and financial performance.
-
The company is undergoing a significant organizational restructuring, including the appointment of a new COO and a split into three segments. While this may be intended to improve efficiency, such changes can introduce uncertainty and disrupt business operations, potentially affecting short-term performance.
| | View Today's Stock Pick |
|
| |
|
|
